- Accession Number
- DBCAT002554 (DBCAT000932, DBCAT002399)
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
- ATC Classification
Drug Drug Description Cyproterone acetate A steroid used in combination with ethinyl estradiol to treat women with severe acne and symptoms of androgenization. Also used alone at much higher doses for palliative treatment of patients with prostate cancer Flutamide An antiandrogen used for locally confined stage B2-C and D-2 metastatic prostate carcinoma. Nilutamide An antineoplastic hormone used to treat prostate cancer. Bicalutamide An androgen receptor inhibitor used to treat Stage D2 metastatic carcinoma of the prostate. Enzalutamide A second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Chlormadinone A progestin indicated in combination with an estrogen for oral combined hormonal contraceptive therapy. Apalutamide An androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Darolutamide An androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer. Ketodarolutamide Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of darolutamide. Chlormadinone acetate A progestin indicated in combination with an estrogen for birth control. Relugolix An oral GnRH receptor antagonist for androgen deprivation therapy in the treatment of advanced prostate cancer. Clascoterone An androgen receptor antagonist used for the topical treatment of acne vulgaris in patients 12 years of age and older.
- Drugs & Drug Targets